Immunotherapy combo before chemo-radiation shows promise for esophageal cancer
NCT ID NCT03044613
First seen Apr 09, 2026 · Last updated Jun 13, 2026 · Updated 14 times
Summary
This study tests whether giving immunotherapy drugs (nivolumab alone or with relatlimab) before standard chemoradiation is safe and feasible for people with operable stage II/III esophageal or gastroesophageal junction cancer. About 32 adults will receive the drugs, then chemoradiation, followed by surgery. The goal is to see if this approach changes the tumor's environment and improves survival without causing major delays in surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Alleghany Health Network
Pittsburgh, Pennsylvania, 15212, United States
-
Baylor University/ Charles A. Sammons Cancer Center
Dallas, Texas, 75246, United States
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.